{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T18:23:40Z","timestamp":1772648620830,"version":"3.50.1"},"reference-count":0,"publisher":"Frontline Medical Communications, Inc.","issue":"117","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,1]]},"DOI":"10.12788\/cutis.1323","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T15:57:43Z","timestamp":1772639863000},"source":"Crossref","is-referenced-by-count":0,"title":["Pathogenic Significance of Serum Syndecan-1 and Syndecan-4 in Psoriasis"],"prefix":"10.12788","volume":"1","author":[{"given":"Mehmet Ali","family":"Yildirim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5043","container-title":["Cutis"],"original-title":[],"link":[{"URL":"https:\/\/cdn.mdedge.com\/files\/s3fs-public\/issues\/articles\/CT117001022.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T15:57:43Z","timestamp":1772639863000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdedge.com\/dermatology\/article\/273176\/psoriasis\/pathogenic-significance-serum-syndecan-1-and-syndecan-4-psoriasis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":0,"journal-issue":{"issue":"117","published-print":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.12788\/cutis.1323","relation":{},"ISSN":["0011-4162"],"issn-type":[{"value":"0011-4162","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,1]]}}}